We scan new podcasts and send you the top 5 insights daily.
Clayton Mellina describes a rare autism case where Transcripta found a cancer drug class that calmed hyperexcitability in patient neurons at lower doses. After clinical behavioral improvements in that single-patient cohort, the team found similar RNA signatures across broader genetic autism disorders, expanding the program.
The company's breakthrough potential comes not from collecting raw DNA, but from linking it at an individual level to a rich set of "phenotype" data, including proteomics, metabolomics, and transcriptomics. This deep, multi-layered dataset from novel populations is what unlocks actionable insights for drug discovery.
Clayton Mellina says Transcripta builds disease signatures from patient single-cell RNA-seq, then screens drugs in cells to create its Drug Gene Atlas. It matches those signatures before committing to one protein target, keeping target identification open until later and widening the therapeutic search. Chris Moxham adds this combines phenotypic screening with efficient target-based work.
Historical failures in CNS drugs stem from treating severe, late-stage pathology. Success will come from using better biomarkers to intervene earlier and combining therapies. The speaker envisions a future of 'rational polypharmacy,' where drugs targeting different pathological drivers (e.g., excitability, inflammation) are used in concert.
Chris Moxham says when a Science paper showed MSH3 knockdown could delay Huntington's repeat expansion, Transcripta queried its internal data and found novel structures already being worked on within minutes. That existing data turned a fresh finding into a program aiming for the clinic next year.
Human genetics doesn't just provide a drug target; it often specifies the therapeutic approach required. Discovering a protective loss-of-function mutation immediately tells researchers to develop an inhibitor (like an antibody or siRNA), accelerating the path from target discovery to molecule design.
The next wave of neuroscience therapeutics is shifting from managing broad symptoms (e.g., in autism) to precision therapies. By identifying genetic underpinnings of a disease, developers can create drugs that target the specific biology of patient subpopulations, aiming for disease modification rather than just symptomatic relief.
The highly personalized, N-of-1 approaches developed for rare diseases are not a niche field. With advanced genetic sequencing, it's becoming clear that every disease is effectively rare and unique to the individual. The lessons from rare disease are creating the foundation for all future medicine.
Derek Small argues the breakthrough in neuroscience mirrors oncology's shift from blunt instruments to targeted therapies. By focusing on underlying pathology like synaptic dysfunction and neuroinflammation, rather than just symptoms, developers can achieve biomarker-based approvals and more effective treatments.
Instead of traditional methods, Regeneron sequences millions of people to find "superhumans"—those with rare genetic mutations that protect them from diseases. By studying these individuals, they identify high-confidence drug targets that mimic these natural protections, aiming for a higher probability of success in development.
The activity of menin inhibitors is not strictly limited to patients with KMT2A or NPM1 mutations. Emerging data shows responses in patients with rare NUC98 rearrangements and those with a specific HOXA9 transcriptome signature, suggesting a wider potential use.